Global COVID-19 Prevention Trial Of Hydroxychloroquine To Resume

A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.

The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus.

The COPCOV study was paused pending review after the treatment trial results.

It is a randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world, and is being led by the Oxford University's Mahidol Oxford Tropical Medicine Research Unit (MORU) in the Thai capital, Bangkok.

US President Donald Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself, even after the US regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

The FDA later revoked emergency use authorisation for the drugs to treat COVID-19, after trials showed they were of no benefit as treatments.

But White, who is co-leadng the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.

"Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomised controlled trial," he said in a statement. "The question whether (it) can prevent COVID-19 or not remains as pertinent as ever."

White's team said recruitment of British health workers would resume this week, and said plans were under way for new sites in Thailand and Southeast Asia, Africa and South America. Results are expected by the end of this year.

(Reporting by Kate Kelland, editing by Paul Sandle and Timothy Heritage)